26/04/2026
The Odyssey 301 Trial will study an investigational vaccine (a vaccine that is being studied), called mRNA-1018 H5, to see whether it may help protect against symptoms of pandemic flu, specifically H5N1 “bird flu”.
H5 “bird flu” is a virus that causes outbreaks in birds, particularly poultry. It has also been found in other animals such as cows. People can become infected through close contact with infected animals, their droppings, or by breathing in the virus particles in a contaminated environment.
In people, symptoms have most commonly been mild and may include eye redness/irritation, fever, cough, headache, sore throat, tiredness, and muscle aches. In some cases, people may develop more serious symptoms such as shortness of breath or difficulty breathing, confusion and seizures and may need care in a hospital.
You cannot catch bird flu by receiving this investigational vaccine.
You may be able to take part if you:
are 18 years of age or older
are in good health (including well-controlled chronic conditions)
have not been treated with antiviral therapies or any vaccines for the last 28 days.
Further study details
Your participation in the Odyssey 301 Trial will last about 7 months.
You will attend an initial screening visit, up to 4 additional clinic visits, and 4 scheduled phone calls with the clinical trial team
You will be given 2 injections about 21 days apart, which will be either:
An investigational mRNA-1018 bird flu vaccine; OR
A placebo (contains no active ingredients
Reasonable travel costs will be reimbursed.
After screening, up to 4 clinic visits + 4 scheduled calls across approximately 7 months.
Each clinic visit lasts approximately 1-3 hours.
You will be asked to complete an electronic diary (eDiary) for 7 days after each injection
Enrolling in this clinical trial is completely your choice. An independent safety board reviews the data regularly; you can leave the study at any time.
Please contact you nearest hub to register your interest. Each hub's contacts details are listed on our website.
